ES2542853T3 - Método para tratar miastenia grave - Google Patents

Método para tratar miastenia grave Download PDF

Info

Publication number
ES2542853T3
ES2542853T3 ES06779285.3T ES06779285T ES2542853T3 ES 2542853 T3 ES2542853 T3 ES 2542853T3 ES 06779285 T ES06779285 T ES 06779285T ES 2542853 T3 ES2542853 T3 ES 2542853T3
Authority
ES
Spain
Prior art keywords
protein
myasthenia gravis
complement
homologue
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06779285.3T
Other languages
English (en)
Inventor
John Hamer
Wynne Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Application granted granted Critical
Publication of ES2542853T3 publication Critical patent/ES2542853T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/16—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans
    • A61B17/1604—Chisels; Rongeurs; Punches; Stamps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
    • A61F2/4603—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/16—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans
    • A61B17/1613—Component parts
    • A61B17/1631—Special drive shafts, e.g. flexible shafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/16—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans
    • A61B17/1662—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans for particular parts of the body
    • A61B17/1671—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans for particular parts of the body for the spine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
    • A61F2/4603—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof
    • A61F2/4611—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for insertion or extraction of endoprosthetic joints or of accessories thereof of spinal prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/16—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans
    • A61B17/1613—Component parts
    • A61B17/1633—Sleeves, i.e. non-rotating parts surrounding the bit shaft, e.g. the sleeve forming a single unit with the bit shaft

Abstract

Un agente derivado de un artrópodo hematófago que se une al complemento C5 para su uso en el tratamiento o prevención de miastenia grave, en el que el agente que se une al complemento C5 es: (a) una proteína que comprende o que consiste en los aminoácidos 19 a 168 de la secuencia de aminoácidos de SEC ID Nº: 2; (b) una proteína que comprende o que consiste en los aminoácidos 1 a 168 de la secuencia de aminoácidos de SEC ID Nº: 2; (c) un homólogo que tiene más del 60 % de identidad de secuencias con la proteína como se define en (a) o (b); o (d) un fragmento de la proteína como se define en (a) o (b) o de un homólogo como se define en (c), en el que dicho fragmento retiene la capacidad para unirse al complemento C5.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
    imagen2
ES06779285.3T 2005-09-09 2006-09-05 Método para tratar miastenia grave Active ES2542853T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0518443.7A GB0518443D0 (en) 2005-09-09 2005-09-09 Method of treating myasthenia gravis
GB0518443 2005-09-09
PCT/GB2006/003265 WO2007028968A1 (en) 2005-09-09 2006-09-05 Method of treating myasthenia gravis

Publications (1)

Publication Number Publication Date
ES2542853T3 true ES2542853T3 (es) 2015-08-12

Family

ID=35221219

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06779285.3T Active ES2542853T3 (es) 2005-09-09 2006-09-05 Método para tratar miastenia grave

Country Status (11)

Country Link
US (3) US9192648B2 (es)
EP (2) EP1931372B1 (es)
JP (1) JP5254792B2 (es)
CN (3) CN101340926A (es)
AU (1) AU2006288985B2 (es)
CA (1) CA2621697C (es)
DK (1) DK1931372T3 (es)
ES (1) ES2542853T3 (es)
GB (1) GB0518443D0 (es)
NZ (1) NZ566789A (es)
WO (2) WO2007028968A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
AU2009313203B2 (en) * 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
AU2011204483B2 (en) 2010-01-08 2016-02-11 Volution Immuno Pharmaceuticals Sa EV576 for use in the treatment of viral infections of the respiratory tract
AU2012273118A1 (en) * 2011-06-20 2014-01-23 St. Louis University Targeting the neuromuscular junction for treatment
CN103796667A (zh) * 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
WO2013126006A1 (en) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
WO2015028558A1 (en) 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
TR201911279T4 (tr) 2013-08-28 2019-08-21 Affibody Ab Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması.
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
KR20190008225A (ko) * 2016-05-13 2019-01-23 델노바 인코퍼레이티드 화학적 신경차단으로 인한 부작용의 치료
UA124734C2 (uk) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Антитіло проти с5 і його застосування
EP3589369A4 (en) 2017-01-09 2020-03-18 DAS-MG, Inc. USE AND COMPOSITION FOR TREATING MYASTHENIA GRAVIS AND OTHER MYASTHENIC SYNDROME
US20200000756A1 (en) * 2017-01-24 2020-01-02 Gt Biopharma, Inc. Neostigmine combination and compositions
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2018193122A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
WO2020053206A1 (en) 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
WO2024039740A2 (en) * 2022-08-16 2024-02-22 Gro Biosciences Inc. Polypeptide compositions containing non-standard glycan stub amino acids and methods of making and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041389A (en) * 1986-01-06 1991-08-20 The Salk Institute For Biological Studies Assays for myasthenia gravis
AU3734093A (en) 1992-02-27 1993-09-13 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US20040014782A1 (en) * 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
BRPI0410876B8 (pt) 2003-06-02 2023-01-24 Evolutec Ltd composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
DK2860251T3 (en) * 2004-02-12 2018-06-06 Archemix Llc APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2007117241A1 (en) 2006-04-12 2007-10-18 Biocryst Pharmaceuticals, Inc. Intramuscular antiviral treatments
US20100105611A1 (en) 2006-09-08 2010-04-29 John Hamer Method of treating respiratory disorders
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
US20080114055A1 (en) * 2006-11-10 2008-05-15 Zoltan Laboratories Llc Thioxanthone Compounds to Reverse Weight Loss
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
EP2236100B1 (en) * 2009-03-30 2017-06-28 Arthrex, Inc. Microfracture instrument
WO2011060077A1 (en) * 2009-11-10 2011-05-19 Spine View, Inc. Angled grinder
US8840668B1 (en) * 2009-11-11 2014-09-23 Nuvasive, Inc. Spinal implants, instruments and related methods
US8740983B1 (en) * 2009-11-11 2014-06-03 Nuvasive, Inc. Spinal fusion implants and related methods
US8562592B2 (en) * 2010-05-07 2013-10-22 Ethicon Endo-Surgery, Inc. Compound angle laparoscopic methods and devices
US20120071876A1 (en) * 2010-09-17 2012-03-22 Stoll E Jordan Microfracture awl
WO2015020956A1 (en) * 2013-08-05 2015-02-12 Blumenthal Scott L Vertebral endplate apparatus and method
US10172650B2 (en) * 2014-10-21 2019-01-08 Warsaw Orthopedic, Inc. Spinal implant system and method
US10265194B2 (en) * 2015-04-01 2019-04-23 Zimmer Biomet Spine, Inc. Insertion instrument with articulating wrist

Also Published As

Publication number Publication date
JP5254792B2 (ja) 2013-08-07
US20200282018A1 (en) 2020-09-10
JP2009508819A (ja) 2009-03-05
CN103505721A (zh) 2014-01-15
US20160166640A1 (en) 2016-06-16
EP1931372A1 (en) 2008-06-18
DK1931372T3 (en) 2015-05-26
WO2007028968A9 (en) 2008-06-12
CA2621697A1 (en) 2007-03-15
GB0518443D0 (en) 2005-10-19
WO2007028968A1 (en) 2007-03-15
NZ566789A (en) 2011-11-25
CN114555013A (zh) 2022-05-27
EP1931372B1 (en) 2015-04-29
US20090209459A1 (en) 2009-08-20
WO2021080910A1 (en) 2021-04-29
EP4048171A1 (en) 2022-08-31
AU2006288985B2 (en) 2011-09-29
AU2006288985A1 (en) 2007-03-15
US9192648B2 (en) 2015-11-24
CN101340926A (zh) 2009-01-07
EP4048171A4 (en) 2023-11-22
CA2621697C (en) 2017-08-29

Similar Documents

Publication Publication Date Title
ES2542853T3 (es) Método para tratar miastenia grave
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
ES2528133T3 (es) Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
NO20063026L (no) Antistoffer
DK2719708T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
AR083293A1 (es) Agentes de union a cd33
EA201790858A2 (ru) Лечение и профилактика амилоидоза
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
AR086510A2 (es) Agentes de union especifica al factor de crecimiento de hepatocitos
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CU23719A3 (es) Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
EA200801942A1 (ru) Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
CO2022003582A2 (es) Métodos para el tratamiento de la oftalmopatía tiroidea